Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US
Generic Versions Of Revlimid And Trokendi Drive Record US Sales
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter.
